Beyond a tumor suppressor: Soluble E‐cadherin promotes the progression of cancer

International Journal of Cancer - Tập 138 Số 12 - Trang 2804-2812 - 2016
Qiping Hu1,2, Jing‐Ya Kuang1,2, Qing‐Kai Yang3, Xiu‐Wu Bian1, Shi‐Cang Yu1
1Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
2Q.-P.H. and J.-Y.K. contributed equally to this study.
3Department of Oncology, The Second Affiliated Hospital of DaLian Medical University, Institute of Cancer Stem Cell, DaLian Medical University, Dalian, Liaoning, 116044 China

Tóm tắt

E‐cadherin (E‐cad) plays important roles in tumorigenesis as well as in tumor progression, invasion and metastasis. This protein exists in two forms: a membrane‐tethered form and a soluble form. Full‐length E‐cad is membrane tethered. As a type I transmembrane glycoprotein, E‐cad mainly mediates adherens junctions between cells and is involved in maintaining the normal structure of epithelial tissues. Soluble E‐cad (sE‐cad) is the extracellular fragment of the protein that is cleaved from the membrane after proteolysis of full‐length E‐cad. The production of sE‐cad undermines adherens junctions, causing a reduction in cell aggregation capacity; furthermore, sE‐cad can diffuse into the extracellular environment and the blood. As a paracrine/autocrine signaling molecule, sE‐cad activates or inhibits multiple signaling pathways and participates in the progression of various types of cancer, such as breast cancer, ovarian cancer, and lung cancer, by promoting invasion and metastasis. This article briefly reviews the role of sE‐cad in tumorigenesis and tumor progression and its significance in clinical therapeutics.

Từ khóa


Tài liệu tham khảo

10.1038/nrm3758

10.1038/nrc3647

10.1016/j.cell.2005.09.021

10.1016/j.bpj.2010.03.051

10.1016/j.cell.2005.09.020

10.1038/ncb2976

10.1002/ijc.27947

10.1111/dote.12024

10.1158/0008-5472.CAN-11-3498

10.1158/0008-5472.CAN-06-0410

10.1083/jcb.147.3.631

10.1186/bcr651

10.1016/j.ajpath.2011.03.028

10.1371/journal.pone.0013665

10.1210/me.2004-0342

Peralta Soler A, 1999, Pcadherin expression in breast carcinoma indicates poor survival, Cancer, 86, 1263, 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.0.CO;2-2

Paredes J, 2005, Pcadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin, Cancer Res, 11, 5869

10.1038/sj.onc.1207439

10.1016/S0002-9440(10)63783-2

10.1136/jcp.2007.052704

10.1002/path.4143

10.1016/S0304-3835(01)00759-5

10.1016/S0002-9440(10)65177-2

10.1083/jcb.148.4.779

10.1038/onc.2009.338

10.4161/cam.20253

10.1016/j.bbcan.2012.05.002

10.1074/jbc.274.27.19347

10.2741/4031

10.1074/mcp.M113.033423

10.1515/BC.2002.016

10.18632/oncotarget.4654

10.1242/jcs.03455

10.1016/j.micpath.2015.05.003

10.1038/embor.2010.114

Davies G, 2001, Matrilysin mediates extracellular cleavage of E‐cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor‐induced cell‐cell dissociation and in vitro invasion, Clin Cancer Res, 7, 3289

10.1074/jbc.M708887200

10.1074/jbc.M006102200

10.1016/j.bbadis.2011.12.015

10.1371/journal.pone.0002153

10.1074/jbc.M208772200

10.1038/sj.emboj.7600136

10.1002/mc.22048

10.1074/jbc.M801329200

10.1002/mc.22048

10.1016/j.yexcr.2010.12.025

10.1038/onc.2012.563

10.1242/jcs.173518

10.1038/nrc2536

10.1016/j.tem.2010.06.007

10.1038/sj.onc.1206197

10.1158/1078-0432.CCR-0846-3

10.1242/dev.045500

10.1016/j.devcel.2010.09.011

10.1073/pnas.1103345108

Liu C, 2011, Regulation and function of the TAZ transcription co‐activator, Int J Biochem Mol Biol, 2, 247

10.3389/fimmu.2013.00455

10.1182/blood-2002-02-0657

10.1189/jlb.0204096

10.1182/blood-2008-06-160945

10.4049/jimmunol.1201540

10.4161/2162402X.2014.990793

10.1073/pnas.1412489111

10.1016/j.immuni.2015.05.023

10.4161/onci.28328

10.1136/annrheumdis-2013-203881

10.1007/s00262-013-1473-z

10.1371/journal.pone.0077281

10.1038/nature10984

10.1016/j.tcb.2012.11.006

10.1038/nature10999

10.1038/ncb1853

10.1038/ncb2900

10.1242/jcs.147926

10.1038/bjc.1998.309

10.1023/B:CLIN.0000017204.38807.22

10.1002/ijc.25438

10.1016/j.jss.2011.11.009

10.1136/gut.48.6.808

10.1200/JCO.2003.08.078

Tsalikidis C, 2013, Soluble E‐cadherin as a diagnostic and prognostic marker in gastric carcinoma, Folia Med, 55, 26, 10.2478/folmed-2013-0024

10.1038/bjc.1998.634

10.4161/cbt.6.2.3629

10.1007/s11033-014-3276-5

10.1016/j.clinbiochem.2013.06.010

10.1002/cncr.28767

Soyama A, 2008, Significance of the serum level of soluble E‐cadherin in patients with HCC, Hepatogastroenterology, 55, 1390

10.1186/1746-1596-7-17

10.1186/s13046-015-0161-6

10.1038/sj.bjc.6602599

10.1111/j.1742-4658.2010.07919.x

10.1158/0008-5472.CAN-06-2808

10.1158/1078-0432.CCR-12-2747

10.1158/1535-7163.MCT-13-0971

Thông tin
Thông tin xuất bản

International Journal of Cancer

Tập 138 Số 12

2804-2812

Thông tin tác giả